Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation.
Adult
Anti-Bacterial Agents
/ pharmacology
Bacteria
/ classification
Drug Resistance, Multiple, Bacterial
/ drug effects
Dysbiosis
/ genetics
End Stage Liver Disease
/ microbiology
Feces
/ microbiology
Female
Gastrointestinal Microbiome
/ drug effects
Humans
Liver Transplantation
/ methods
Male
Middle Aged
Prospective Studies
RNA, Ribosomal, 16S
/ genetics
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
17 10 2019
17 10 2019
Historique:
received:
11
04
2019
accepted:
23
09
2019
entrez:
19
10
2019
pubmed:
19
10
2019
medline:
25
1
2020
Statut:
epublish
Résumé
Infections by multidrug-resistant bacteria (MDRB) remain a leading cause of morbidity and mortality after liver transplantation (LT). Gut dysbiosis characteristic of end-stage liver disease may predispose patients to intestinal MDRB colonization and infection, in turn exacerbating dysbiosis. However, relationships between MDRB colonization and dysbiosis after LT remain unclear. We prospectively recruited 177 adult patients undergoing LT at a single tertiary care center. 16 S V3-V4 rRNA sequencing was performed on 723 fecal samples collected pre-LT and periodically until one-year post-LT to test whether MDRB colonization was associated with decreased microbiome diversity. In multivariate linear mixed-effect models, MDRB colonization predicts reduced Shannon α-diversity, after controlling for underlying liver disease, antibiotic exposures, and clinical complications. Importantly, pre-LT microbial markers predict subsequent colonization by MDRB. Our results suggest MDRB colonization as a major, previously unrecognized, marker of persistent dysbiosis. Therapeutic approaches accounting for microbial and clinical factors are needed to address post-transplant microbiome health.
Identifiants
pubmed: 31624266
doi: 10.1038/s41467-019-12633-4
pii: 10.1038/s41467-019-12633-4
pmc: PMC6797753
doi:
Substances chimiques
Anti-Bacterial Agents
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4715Subventions
Organisme : NIAID NIH HHS
ID : R01 AI116939
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001875
Pays : United States
Références
Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
Ann Hepatol. 2006 Apr-Jun;5(2):77-85
pubmed: 16807513
Sci Rep. 2017 Jun 19;7(1):3762
pubmed: 28630433
Clin Microbiol Infect. 2014 Sep;20 Suppl 7:49-73
pubmed: 24861521
Microb Ecol Health Dis. 2015 May 29;26:27663
pubmed: 26028277
Genome Biol. 2004;5(10):R80
pubmed: 15461798
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10467-10472
pubmed: 28900004
Dig Dis. 2011;29(6):518-24
pubmed: 22179206
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Am J Physiol. 1998 Dec;275(6):G1252-8
pubmed: 9843760
Clin Infect Dis. 2017 May 1;64(9):1147-1153
pubmed: 28402408
Drug Metab Dispos. 2019 Mar;47(3):194-202
pubmed: 30598508
Eur J Gastroenterol Hepatol. 1999 Apr;11(4):409-12
pubmed: 10321758
Liver Int. 2018 Jan;38(1):50-58
pubmed: 28561276
Lancet. 2016 Jan 16;387(10015):285-95
pubmed: 26603921
Nature. 2014 Sep 4;513(7516):59-64
pubmed: 25079328
Clin Infect Dis. 2018 Aug 31;67(6):905-912
pubmed: 29718144
Am J Infect Control. 2011 Aug;39(6):506-10
pubmed: 21492962
Sci Transl Med. 2012 Jun 6;4(137):137rv5
pubmed: 22674555
Transpl Infect Dis. 2015 Apr;17(2):174-84
pubmed: 25728703
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Microbiome. 2017 Mar 3;5(1):27
pubmed: 28253908
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Rev Microbiol. 2017 Oct;15(10):630-638
pubmed: 28626231
Hepatobiliary Surg Nutr. 2013 Jun;2(3):142-7
pubmed: 24570932
PLoS One. 2010 Mar 24;5(3):e9836
pubmed: 20352091
Ann Epidemiol. 2016 Nov;26(11):810-815
pubmed: 27751631
J Stat Softw. 2016;75:
pubmed: 32655332
Liver Transpl. 2015 Dec;21(12):1511-9
pubmed: 26136397
Transplant Direct. 2017 Mar 10;3(4):e144
pubmed: 28405600
Am J Physiol Gastrointest Liver Physiol. 2012 May 1;302(9):G966-78
pubmed: 22241860
BMC Gastroenterol. 2014 Feb 24;14:40
pubmed: 24564202
J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S25-7
pubmed: 26447960
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1433-8
pubmed: 26905904
Aliment Pharmacol Ther. 2009 Jun 15;29(12):1273-81
pubmed: 19302262
Cell. 2004 Jul 23;118(2):229-41
pubmed: 15260992
Am J Transplant. 2005 Jan;5(1):125-30
pubmed: 15636620
Antimicrob Agents Chemother. 2009 Oct;53(10):4264-9
pubmed: 19667289
Hepatology. 2011 Aug;54(2):562-72
pubmed: 21574172
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922
Hepatology. 2014 Mar;59(3):1144-65
pubmed: 24716201
Clin Infect Dis. 2018 Aug 31;67(6):869-877
pubmed: 29718124
Gut. 2018 Mar;67(3):534-541
pubmed: 28213609
J Hepatol. 1991 Mar;12(2):162-9
pubmed: 2050995
Infect Immun. 2012 Jan;80(1):62-73
pubmed: 22006564
Hepatology. 2013 Feb;57(2):601-9
pubmed: 23055155
Clin Infect Dis. 2019 Aug 1;69(4):604-613
pubmed: 30383203
Trends Immunol. 2005 Jun;26(6):326-33
pubmed: 15922949
Am J Surg. 2011 Apr;201(4):498-502
pubmed: 20619394
Clin Gastroenterol Hepatol. 2015 Sep;13(9):1567-74.e3; quiz e143-4
pubmed: 26044318
Liver Transpl. 2016 May;22(5):579-81
pubmed: 26934673
Microb Ecol. 2013 Apr;65(3):781-91
pubmed: 23504024